TCR2 Therapeutics presents preclinical data on Gavo-cel

TCR2 Therapeutics announced the poster presentation of new preclinical data at the Society for Immunotherapy of Cancer, SITC, Conference 37th Annual Meeting, taking place November 8-12, 2022. The poster entitled "The Functional Activity of gavo-cel TRuC-T Cells is Not Impaired by Soluble Mesothelin" highlights preclinical data evaluating the impact of soluble mesothelin at high, supraphysiological levels on the functional activity of the Company’s proprietary autologous and allogeneic mesothelin-directed T Cell Receptor Fusion Construct T cells. Mesothelin, a protein which plays an active role in both malignant transformation and tumor aggressiveness, undergoes shedding in the tumor microenvironment, generating soluble mesothelin. These sMSLN levels are associated with tumor burden in malignant pleural/peritoneal mesothelioma. To address the potential impact of sMSLN on the function of gavo-cel, acute and chronic in vitro challenge studies were performed in the presence of supraphysiological sMSLN levels. Levels of sMSLN 50-fold higher than were measured in MPM patients had no observed impact on the functional activity of gavo-cel T cells with respect to tumor cell killing and cytokine production.